Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement
about
PodocytesHemolytic uremic syndrome: toxins, vessels, and inflammationC3a receptor antagonist ameliorates inflammatory and fibrotic signals in type 2 diabetic nephropathy by suppressing the activation of TGF-β/smad3 and IKBα pathwayHaemolytic uraemic syndrome.Hypertension and mild chronic kidney disease persist following severe haemolytic uraemic syndrome caused by Shiga toxin-producing Escherichia coli O104:H4 in adults.CFH gene mutation in a case of Shiga toxin-associated hemolytic uremic syndrome (STEC-HUS).Human mannose-binding lectin inhibitor prevents Shiga toxin-induced renal injuryWnt/β-catenin signalling and podocyte dysfunction in proteinuric kidney disease.A previously unrecognized role of C3a in proteinuric progressive nephropathy.Podocyte-actin dynamics in health and disease.Typical Hus: Evidence of Acute Phase Complement Activation from a Daycare Outbreak.Complement C5-inhibiting therapy for the thrombotic microangiopathies: accumulating evidence, but not a panacea.Microvesicle Involvement in Shiga Toxin-Associated Infection.Shiga toxin triggers endothelial and podocyte injury: the role of complement activation.The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.Moderator's view: Biomarkers in glomerular diseases--translated into patient care or lost in translation?Modeling Hemolytic-Uremic Syndrome: In-Depth Characterization of Distinct Murine Models Reflecting Different Features of Human Disease.
P2860
Q26766118-9F9E1A71-6661-4FDF-B57F-502BBDAD6908Q28083347-221E3645-97B5-4980-B8B4-FAA43D5A1552Q28545168-E90FFC7D-AC80-4968-A5B3-D7FDF5E91F4BQ30244707-5DEC86A6-8E96-468A-9DFB-437BCCF30DFEQ33424483-1D8AE852-B23E-43AD-A138-32FCDB17D78CQ33426147-32CC75B3-FC01-4A58-A2CD-02DD957726EFQ33433630-E0DD3FAB-F7B0-4613-A94C-2118D8DB1E73Q36908181-9729D580-C9B3-470C-A3F8-2666B3B3ADFDQ37040241-615EECAE-A171-4060-8E82-90C753851008Q38940494-D9B87C5D-05EF-473A-8B7C-62EA49325469Q40652002-600B051C-845B-4048-9166-98867A92AC8AQ42086661-D23F8A72-FCDC-471E-A549-A9A7CA2AC68CQ47127903-8D07F49E-B2D6-47F3-AB9E-03104ADEB8B5Q47321222-D462A412-E1D0-4972-AE17-A6D4EE91E935Q48241051-708D98C4-E8B8-4798-AAD1-AAB4632CEAAFQ53499269-40092109-54B0-42B6-8085-42965D3316A6Q55516340-66C8FFAB-DAED-45A9-A33D-FD99B4EA7590
P2860
Shiga toxin promotes podocyte injury in experimental hemolytic uremic syndrome via activation of the alternative pathway of complement
description
2014 nî lūn-bûn
@nan
2014 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Shiga toxin promotes podocyte ...... ernative pathway of complement
@ast
Shiga toxin promotes podocyte ...... ernative pathway of complement
@en
type
label
Shiga toxin promotes podocyte ...... ernative pathway of complement
@ast
Shiga toxin promotes podocyte ...... ernative pathway of complement
@en
prefLabel
Shiga toxin promotes podocyte ...... ernative pathway of complement
@ast
Shiga toxin promotes podocyte ...... ernative pathway of complement
@en
P2093
P2860
P50
P356
P1476
Shiga toxin promotes podocyte ...... ernative pathway of complement
@en
P2093
Anna Pezzotta
Carlamaria Zoja
Daniela Corna
Daniela Rottoli
Debora Conti
Joshua M Thurman
Marina Morigi
Monica Locatelli
Paola Rizzo
Simona Buelli
P2860
P304
P356
10.1681/ASN.2013050450
P577
2014-02-27T00:00:00Z